Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-04-29
|
GLPG1972 |
osteoarthritis |
preclinical |
Galapagos (Belgium) |
|
2017-04-28
|
eptinezumab - ALD403 |
chronic migraine |
2b |
Alder Biopharmaceuticals (USA - WA) |
CNS diseases - Neurological diseases |
2017-04-27
|
SD-809 - deutetrabenazine |
tardive dyskinesia |
3 |
Teva Pharmaceutical Industries (Israel) |
Neurological diseases - CNS diseases |
2017-04-27
|
AZ8838, AZ3451 |
|
|
Heptares Therapeutics (UK), a wholly-owned subsidiary of Sosei Group (Japan) AstraZeneca (UK) |
|
2017-04-27
|
QR-110 |
Leber’s congenital amaurosis type 10 |
1-2 |
ProQR Therapeutics (The Netherlands) |
Rare diseases - Genetic diseases - Ophtalmological diseases |
2017-04-27
|
MRG-201 |
pathological fibrosis |
1 |
Miragen Therapeutics (USA - Co) |
Fibrotic diseases |
2017-04-26
|
inclisiran (ALN-PCSsc) |
atherosclerotic cardiovascular disease (ASCVD, familial hypercholesterolemia (FH), |
3 |
Alnylam Therapeutics (USA - MA) The Medicines Company (USA - NJ) |
Cardiovascular diseases |
2017-04-25
|
filgotinib and GS-9876 |
cutaneous lupus erythematosus |
2 |
Galapagos (Belgium) |
Autoimmune diseases – Inflammatory diseases - Dermatological diseases |
2017-04-24
|
belinostat (Beleodaq®) |
relapsed or refractory peripheral T-cell lymphoma |
|
Clinigen (UK) Onxeo (France) |
Cancer - Oncology |
2017-04-24
|
abemaciclib (LY2835219) |
hormone receptor-positive, HER2-negative locoregionally recurrent or metastatic breast cancer |
3 |
Eli Lilly (USA - IN) |
Cancer - Oncology |
2017-04-24
|
Resolaris® - ATYR1940 |
limb girdle muscular dystrophy (LGMD) |
1-2 |
Atyr Pharma (USA - CA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2017-04-24
|
Resolaris® |
facioscapulohumeral muscular dystrophy |
1b-2 |
Atyr Pharma (USA - CA) |
Rare diseases - Genetic diseases - Neuromuscular diseases |
2017-04-22
|
JNJ-4178 (AL-335, odalasvir (ACH-3102) and simeprevir= |
chronic hepatitis C |
2 |
Alios Biopharma, a J&J company (USA - NJ) Achillion Pharmaceuticals (USA - CT) |
Infectious diseases |
2017-04-22
|
A4250 |
primary biliary cirrhosis, cholestatic pruritus |
2 |
Albireo (Sweden) |
Autoimmune diseases - Hepatic diseases - Liver diseases |
2017-04-22
|
MK-3682B (uprifosbuvir/grazoprevir/rusazvir) |
hepatitis C |
2 |
Merck&Co (USA - NJ) |
Infectious diseases |
2017-04-22
|
BMS-986036 (Pegylated FGF21) |
NASH (non-alcoholic steatohepatitis) |
2 |
BMS (USA - NY) |
Hepatic diseases - Liver diseases |
2017-04-21
|
BGB-290 and BGB-A317 |
advanced solid tumors |
1b |
BeiGene (China) |
Cancer - Oncology |
2017-04-21
|
GS-0976 ( NDI-010976) |
NASH (non-alcoholic steatohepatitis) |
|
Gilead Sciences (USA - CA) |
Hepatic diseases - Liver diseases |
2017-04-20
|
CA4P and everolimus |
neuroendocrine tumors |
1 |
Mateon Therapeutics (USA - CA) |
Cancer - Oncology |
2017-04-20
|
IMP321 and pembrolizumab |
melanoma |
1 |
Prima Biomed (Australia) |
Cancer - Oncology |